Board of Directors
The Board of Directors maintain the ethos of the company, ensuring corporate goals are followed consistently
Dr Robert Scoffin
Chairman and CEO
Rob is an expert in the fields of molecular modeling and cheminformatics. His previous roles include CEO of Amedis and VP, Europe at CambridgeSoft. His DPhil is in Chemistry from the University of Oxford. Rob is passionate about applying computational methods to help meet medical challenges. He believes drug discovery and design can be streamlined and improved through the use of computational methods, resulting in better drugs being brought to market sooner. Rob is a Fellow of the Royal Society of Chemistry.
Dr Mark Mackey
Chief Scientific Officer
Mark was one of the founders of Cresset when the company was formed in 2002. He became CSO in 2013 and heads up our scientific team. He has made fundamental contributions to our underlying scientific approach and to the development of the software. He works hard to extend the scientific base of the company in a way that is consistent with our reputation of rigorous scientific excellence. His team’s current research includes new ways of applying the XED force fields to proteins and improving the handling of water molecules. Mark’s previous experience includes roles at Napp Pharmaceuticals and Merck, Sharpe and Dohme. His PhD is in Chemistry from the University of Cambridge and he is a Fellow of the Royal Society of Chemistry.
Dr Tim Cheeseright
Chief Technology Officer
After a DPhil in Chemistry at the University of Oxford, Tim gained experience as a medicinal chemist and a molecular modeler at Peptide Therapeutics and Medivir. Tim was a co-founder of Cresset when the company was formed in 2002 and has been instrumental in developing the easy to use scientific software that characterises Cresset today. As CTO Tim is responsible for Cresset’s range of software for computational chemists and medicinal chemists. Tim's commitment to innovative, usable and accessible science is evident in every release.
Dr David Bardsley
Commercial Director
As Commercial Director David heads up the Sales and Marketing team. Through his global role and direct interactions with people across industry and academia, he is always seeking ways to serve our customers better. His fundamental rule is to listen to the customer in order to discover and understand their needs. David has extensive commercial experience with software and technology solutions in the scientific market. Prior to Cresset, David was responsible for business development and strategic commercial growth, with Symyx Technologies and CambridgeSoft. David has a PhD and BSc in Microbiology from the University of Wales, Cardiff.
Rebecca Scutt
Chief Operating Officer
After graduating from Newcastle University, Rebecca led the administration and customer relations team at a software company in London. She joined Cresset in 2012, was appointed as Company Secretary in 2017 and COO in 2021. Rebecca has responsibility for administrative, IT and HR functions of the business.
John Leighton
Chief Financial Officer
John has over 20 years experience as a Chartered Accountant, with wide experience of international high-growth and scaling tech companies. After training as an accountant he joined Ernst & Young before moving to industry. John has an MPhys from the University of Manchester and is a Fellow Chartered Accountant with the Institute of Chartered Accountants in England and Wales. John advises on financial strategy and provides experienced leadership of our finance function.
Non-Executive Directors
Advise and contribute to continued growth
Dr David Newble
Non-Executive Director
David brings a wealth of experience in the life sciences, technology and services sectors, which will complement the existing skills and experiences around the Board table. He currently also serves as Managing Director of SPT Labtech.
Angus Conroy
Non-Executive Director
Angus is a partner at technology growth equity firm Scottish Equity Partners (SEP), primarily focused on software scale-ups. He has a particular interest in the life sciences technology market where innovation can drive improvements in the drug development process. Angus has led and managed investments across the software sector, and he sits on the boards of several fast growing, international companies. He works closely with investee businesses to sustainably build growth and value.